Targeted Sequencing of Known Cancer Genes in Anaplastic Meningioma
Research type
Research Study
Full title
Targeted Sequencing of Known Cancer Genes in Anaplastic Meningioma
IRAS ID
131513
Contact name
Thomas Santarius
Contact email
Sponsor organisation
Cambridge University NHS Foundation Trust,
Research summary
Anaplastic meningiomas are rare, malignant variant of a meningioma comprising some 2% of all meningiomas. Unlike their non-anaplastic counterpart, anaplastic meningiomas recur early and grow relentlessly even after numerous radical surgeries, eventually leading to the death of the patient. At present there is no adjuvant treatment (radiotherapy, chemotherapy or else) that is effective in controlling these tumours. We and others have earlier this year published the discovery of a number of new cancer genes underlying the development and maintenance of non-anaplastic meningiomas. Undoubtedly, anaplastic meningiomas, like their non-anaplastic variants and all other cancers, have mutated genes and these determine their anaplastic phenotype. By discovering and describing these genetic aberrations, it will be possible to rationally select effective medications from the already existing armamentarium of chemotherapeutic agents. In addition, novel target genes may be discovered which in turn can direct the development of new compounds specifically targeting these genetic defects.
REC name
Yorkshire & The Humber - Leeds West Research Ethics Committee
REC reference
14/YH/0101
Date of REC Opinion
26 Mar 2014
REC opinion
Favourable Opinion